Dawn Wilson

1.1k total citations
33 papers, 847 citations indexed

About

Dawn Wilson is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Dawn Wilson has authored 33 papers receiving a total of 847 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 15 papers in Genetics and 13 papers in Hematology. Recurrent topics in Dawn Wilson's work include Hemoglobinopathies and Related Disorders (9 papers), TGF-β signaling in diseases (8 papers) and Renal cell carcinoma treatment (7 papers). Dawn Wilson is often cited by papers focused on Hemoglobinopathies and Related Disorders (9 papers), TGF-β signaling in diseases (8 papers) and Renal cell carcinoma treatment (7 papers). Dawn Wilson collaborates with scholars based in United States, Germany and Italy. Dawn Wilson's co-authors include Matthew L. Sherman, Kenneth M. Attie, Ty McClure, Amelia E. Pearsall, Yijun Yang, Niels Borgstein, Carolyn H. Condon, Kathryn Selby, Diana M. Escolar and Hugh J. McMillan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Dawn Wilson

33 papers receiving 824 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dawn Wilson United States	13	462	238	229	228	90	33	847
Shenglin Ma Switzerland	5	358 0.8×	68 0.3×	255 1.1×	127 0.6×	44 0.5×	7	830
Abbas Jafari Denmark	17	431 0.9×	156 0.7×	95 0.4×	63 0.3×	34 0.4×	35	823
Puneet Agarwal United States	15	383 0.8×	285 1.2×	36 0.2×	481 2.1×	52 0.6×	27	1.1k
John R. Glossop United Kingdom	16	281 0.6×	104 0.4×	53 0.2×	79 0.3×	43 0.5×	22	737
Heather A. O’Leary United States	14	314 0.7×	182 0.8×	48 0.2×	360 1.6×	44 0.5×	26	869
Esterina D’Asti Canada	16	905 2.0×	79 0.3×	58 0.3×	100 0.4×	41 0.5×	21	1.2k
Zi‐Fan Yu United States	11	546 1.2×	75 0.3×	476 2.1×	55 0.2×	68 0.8×	19	1.5k
Jasper Chen United States	11	433 0.9×	125 0.5×	27 0.1×	231 1.0×	96 1.1×	14	1.3k
Chiara Baldo Italy	15	371 0.8×	50 0.2×	103 0.4×	64 0.3×	34 0.4×	31	947
Binxia Yang United States	19	285 0.6×	53 0.2×	82 0.4×	52 0.2×	63 0.7×	34	879

Countries citing papers authored by Dawn Wilson

Since Specialization

Citations

This map shows the geographic impact of Dawn Wilson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawn Wilson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawn Wilson more than expected).

Fields of papers citing papers by Dawn Wilson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dawn Wilson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawn Wilson. The network helps show where Dawn Wilson may publish in the future.

Co-authorship network of co-authors of Dawn Wilson

This figure shows the co-authorship network connecting the top 25 collaborators of Dawn Wilson. A scholar is included among the top collaborators of Dawn Wilson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dawn Wilson. Dawn Wilson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sharma, Manish, Melissa L. Johnson, Igor Puzanov, et al.. (2024). 758 GLIMMER-01: phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors. Regular and Young Investigator Award Abstracts. A862–A862. 3 indexed citations

Voss, Martin H., Rupal S. Bhatt, Elizabeth R. Plimack, et al.. (2016). The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. Clinical Cancer Research. 23(14). 3557–3565. 21 indexed citations

Jimeno, Antonio, Marshall R. Posner, Lori J. Wirth, et al.. (2016). A phase 2 study of dalantercept, an activin receptor‐like kinase‐1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 122(23). 3641–3649. 28 indexed citations

Chen, Nianhang, Abderrahmane Laadem, Dawn Wilson, et al.. (2016). Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Beta-Thalassemia: Preliminary Results from Phase 2 Studies. Blood. 128(22). 2463–2463. 8 indexed citations

Piga, Antonio, Immacolata Tartaglione, Rita Gamberini, et al.. (2016). Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia. Blood. 128(22). 851–851. 13 indexed citations

Giagounidis, Aristoteles, Uwe Platzbecker, Ulrich Germing, et al.. (2015). Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study. Blood. 126(23). 92–92. 22 indexed citations

Voss, Martin H., Elizabeth R. Plimack, Brian I. Rini, et al.. (2015). DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1.. Journal of Clinical Oncology. 33(7_suppl). 407–407. 2 indexed citations

Piga, Antonio, Silverio Perrotta, Maria Rita Gamberini, et al.. (2015). Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study. Blood. 126(23). 752–752. 7 indexed citations

Platzbecker, Uwe, Ulrich Germing, Aristoteles Giagounidis, et al.. (2015). Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study. Blood. 126(23). 2862–2862. 5 indexed citations

10.

Platzbecker, Uwe, Ulrich Germing, Aristoteles Giagounidis, et al.. (2015). 53 LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY. Leukemia Research. 39. S25–S25. 18 indexed citations

11.

Piga, Antonio, Silverio Perrotta, Angela Melpignano, et al.. (2014). ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study. Blood. 124(21). 53–53. 10 indexed citations

12.

Attie, Kenneth M., Mark Allison, Ty McClure, et al.. (2014). A phase 1 study of ACE‐536, a regulator of erythroid differentiation, in healthy volunteers. American Journal of Hematology. 89(7). 766–770. 88 indexed citations

13.

Jimeno, Antonio, Marshall R. Posner, Jared Weiss, et al.. (2014). Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck.. Journal of Clinical Oncology. 32(15_suppl). 6045–6045. 5 indexed citations

14.

Bendell, Johanna C., Michael S. Gordon, Herbert I. Hurwitz, et al.. (2013). Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer. Clinical Cancer Research. 20(2). 480–489. 47 indexed citations

15.

Sherman, Matthew L., Niels Borgstein, Dawn Wilson, et al.. (2013). Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal women. The Journal of Clinical Pharmacology. 53(11). 1121–1130. 86 indexed citations

16.

Atkins, Michael B., Rupal S. Bhatt, Martin H. Voss, et al.. (2013). Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 31(15_suppl). TPS4595–TPS4595. 1 indexed citations

17.

Attie, Kenneth M., et al.. (2012). ACE-536 Increases Hemoglobin in Healthy Postmenopausal Women: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study. Blood. 120(21). 3194–3194. 1 indexed citations

18.

Campbell, Craig, Diana M. Escolar, Mark A. Tarnopolsky, et al.. (2012). A Phase 2, Randomized, Placebo-Controlled, Multiple Ascending-Dose Study of ACE-031, a Soluble Activin Receptor Type IIB, in Boys with Duchenne Muscular Dystrophy (DMD) (P04.088). Neurology. 78(Meeting Abstracts 1). P04.088–P04.088. 3 indexed citations

19.

Bendell, Johanna C., Michael S. Gordon, Herbert I. Hurwitz, et al.. (2011). Abstract 3276: A Phase 1 dose escalating study with ACE-041, a novel inhibitor of ALK1 mediated angiogenesis, in patients with advanced solid tumors. Cancer Research. 71(8_Supplement). 3276–3276. 2 indexed citations

20.

Mair, H., A. Wang, Gordon Gammie, et al.. (2007). A 65-nm Mobile Multimedia Applications Processor with an Adaptive Power Management Scheme to Compensate for Variations. 224–225. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact